BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

666 related articles for article (PubMed ID: 33269380)

  • 21. Knockdown of KLF5 suppresses hypoxia-induced resistance to cisplatin in NSCLC cells by regulating HIF-1α-dependent glycolysis through inactivation of the PI3K/Akt/mTOR pathway.
    Gong T; Cui L; Wang H; Wang H; Han N
    J Transl Med; 2018 Jun; 16(1):164. PubMed ID: 29898734
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Isoflurane Promotes Non-Small Cell Lung Cancer Malignancy by Activating the Akt-Mammalian Target of Rapamycin (mTOR) Signaling Pathway.
    Zhang W; Shao X
    Med Sci Monit; 2016 Nov; 22():4644-4650. PubMed ID: 27897153
    [TBL] [Abstract][Full Text] [Related]  

  • 23. microRNA-145-3p inhibits non-small cell lung cancer cell migration and invasion by targeting PDK1 via the mTOR signaling pathway.
    Chen GM; Zheng AJ; Cai J; Han P; Ji HB; Wang LL
    J Cell Biochem; 2018 Jan; 119(1):885-895. PubMed ID: 28661070
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CDKL3 Promotes Non-small Cell Lung Cancer by Suppressing Autophagy Via Activation of PI3K/Akt/mTOR Pathway.
    Li R; Chai L; Lei L; Guo R; Wen X
    Mol Biotechnol; 2023 Sep; 65(9):1421-1431. PubMed ID: 36630073
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Eupafolin regulates non-small-cell lung cancer cell proliferation,migration, and invasion by suppressing MMP9 and RhoA via FAK/PI3K/AKT signaling pathway.
    Wang X; Huang M; Xie W; Ding Q; Wang T
    J Biosci; 2023; 48():. PubMed ID: 36695419
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ROR1-AS1 knockdown inhibits growth and invasion and promotes apoptosis in NSCLC cells by suppression of the PI3K/Akt/mTOR pathway.
    Li F; Gu F; Li Q; Zhai C; Gong R; Zhu X
    J Biochem Mol Toxicol; 2021 May; 35(5):e22726. PubMed ID: 33491326
    [TBL] [Abstract][Full Text] [Related]  

  • 27. microRNA-935 is reduced in non-small cell lung cancer tissue, is linked to poor outcome, and acts on signal transduction mediator E2F7 and the AKT pathway.
    Wang C; Li S; Xu J; Niu W; Li S
    Br J Biomed Sci; 2019 Jan; 76(1):17-23. PubMed ID: 30203720
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MiR-206 inhibits HGF-induced epithelial-mesenchymal transition and angiogenesis in non-small cell lung cancer via c-Met /PI3k/Akt/mTOR pathway.
    Chen QY; Jiao DM; Wu YQ; Chen J; Wang J; Tang XL; Mou H; Hu HZ; Song J; Yan J; Wu LJ; Chen J; Wang Z
    Oncotarget; 2016 Apr; 7(14):18247-61. PubMed ID: 26919096
    [TBL] [Abstract][Full Text] [Related]  

  • 29. microRNA-548l is involved in the migration and invasion of non-small cell lung cancer by targeting the AKT1 signaling pathway.
    Liu C; Yang H; Xu Z; Li D; Zhou M; Xiao K; Shi Z; Zhu L; Yang L; Zhou R
    J Cancer Res Clin Oncol; 2015 Mar; 141(3):431-41. PubMed ID: 25245053
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Circular RNA circDLG1 (has_circ_0068706) functions as an oncogene in nonsmall cell lung cancer through regulating AKT/mTOR signaling and direct binding to miR-144.
    Chen YF; Xu AP
    Kaohsiung J Med Sci; 2023 May; 39(5):446-457. PubMed ID: 36876724
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of microRNA-513b on cell proliferation, apoptosis, invasion, and migration by targeting HMGB3 through regulation of mTOR signaling pathway in non-small-cell lung cancer.
    Wang J; Sheng Z; Cai Y
    J Cell Physiol; 2019 Jul; 234(7):10934-10941. PubMed ID: 30623409
    [TBL] [Abstract][Full Text] [Related]  

  • 32. OTUB2 stabilizes U2AF2 to promote the Warburg effect and tumorigenesis via the AKT/mTOR signaling pathway in non-small cell lung cancer.
    Li J; Cheng D; Zhu M; Yu H; Pan Z; Liu L; Geng Q; Pan H; Yan M; Yao M
    Theranostics; 2019; 9(1):179-195. PubMed ID: 30662561
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MicroRNA-20a-5p suppresses tumor angiogenesis of non-small cell lung cancer through RRM2-mediated PI3K/Akt signaling pathway.
    Han J; Hu J; Sun F; Bian H; Tang B; Fang X
    Mol Cell Biochem; 2021 Feb; 476(2):689-698. PubMed ID: 33125611
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PTPRH promotes the progression of non-small cell lung cancer via glycolysis mediated by the PI3K/AKT/mTOR signaling pathway.
    Wang S; Cheng Z; Cui Y; Xu S; Luan Q; Jing S; Du B; Li X; Li Y
    J Transl Med; 2023 Nov; 21(1):819. PubMed ID: 37974250
    [TBL] [Abstract][Full Text] [Related]  

  • 35. LncRNA SNHG12 regulates the miR-101-3p/CUL4B axis to mediate the proliferation, migration and invasion of non-small cell lung cancer.
    Xie FW; Liu JC
    Kaohsiung J Med Sci; 2021 Aug; 37(8):664-674. PubMed ID: 34002487
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MiR-320a-3p/ELF3 axis regulates cell metastasis and invasion in non-small cell lung cancer via PI3K/Akt pathway.
    Zhao W; Sun Q; Yu Z; Mao S; Jin Y; Li J; Jiang Z; Zhang Y; Chen M; Chen P; Chen D; Xu H; Ding S; Yu Z
    Gene; 2018 Sep; 670():31-37. PubMed ID: 29803922
    [TBL] [Abstract][Full Text] [Related]  

  • 37. miR-31-5p modulates cell progression in lung adenocarcinoma through TNS1/p53 axis.
    Zhu C; Wang S; Zheng M; Chen Z; Wang G; Ma J; Zhang B; Huang W; Sun X; Wang C
    Strahlenther Onkol; 2022 Mar; 198(3):304-314. PubMed ID: 35037949
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anwuligan inhibits the progression of non-small cell lung cancer via let-7c-3p/PI3K/AKT/mTOR axis.
    Niu H; Wang D; Wen T; Liu H; Jie J; Song L; Li D
    Cancer Med; 2023 Mar; 12(5):5908-5925. PubMed ID: 36412203
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HAX1 enhances the survival and metastasis of non-small cell lung cancer through the AKT/mTOR and MDM2/p53 signaling pathway.
    Liang Z; Zhong Y; Meng L; Chen Y; Liu Y; Wu A; Li X; Wang M
    Thorac Cancer; 2020 Nov; 11(11):3155-3167. PubMed ID: 32926529
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MicroRNA-448/EPHA7 axis regulates cell proliferation, invasion and migration via regulation of PI3K/AKT signaling pathway and epithelial-to-mesenchymal transition in non-small cell lung cancer.
    Liu HY; Chang J; Li GD; Zhang ZH; Tian J; Mu YS
    Eur Rev Med Pharmacol Sci; 2020 Jun; 24(11):6139-6149. PubMed ID: 32572879
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.